Decades of legal precedent defending the authority of Congress and the Medicare agency threaten to stand in the way of the pharmaceutical industry’s pursuit to stop the federal government from negotiating lower drug prices, lawyers and drug pricing analysts say.
The leading industry trade group, the Pharmaceutical Research and Manufacturers of America, took a stab last week at arguing the drug price negotiation provisions of the Inflation Reduction Act are unconstitutional, following similar lawsuits filed by member companies
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.